Literature DB >> 27216194

Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway.

Yasminka Jakubek1, Wenhua Lang2, Selina Vattathil1, Melinda Garcia2, Li Xu2, Lili Huang1, Suk-Young Yoo3, Li Shen3, Wei Lu2, Chi-Wan Chow4, Zachary Weber5, Gareth Davies5, Jing Huang1, Carmen Behrens4, Neda Kalhor6, Cesar Moran6, Junya Fujimoto2, Reza Mehran7, Randa El-Zein8, Stephen G Swisher7, Jing Wang3, Jerry Fowler1, Avrum E Spira9, Erik A Ehli5, Ignacio I Wistuba2, Paul Scheet10, Humam Kadara11.   

Abstract

Visually normal cells adjacent to, and extending from, tumors of the lung may carry molecular alterations characteristics of the tumor itself, an effect referred to as airway field of cancerization. This airway field has been postulated as a model for early events in lung cancer pathogenesis. Yet the genomic landscape of somatically acquired molecular alterations in airway epithelia of lung cancer patients has remained unknown. To begin to fill this void, we sought to comprehensively characterize the genomic architecture of chromosomal alterations inducing allelic imbalance (AI) in the airway field of the most common type of lung tumors, non-small cell lung cancer (NSCLC). To do so, we conducted a genome-wide survey of multiple spatially distributed normal-appearing airways, multiregion tumor specimens, and uninvolved normal tissues or blood from 45 patients with early-stage NSCLC. We detected alterations in airway epithelia from 22 patients, with an increased frequency in NSCLCs of squamous histology. Our data also indicated a spatial gradient of AI in samples at closer proximity to the NSCLC. Chromosome 9 displayed the highest levels of AI and comprised recurrent independent events. Furthermore, the airway field AI included oncogenic gains and tumor suppressor losses in known NSCLC drivers. Our results demonstrate that genome-wide AI is common in the airway field of cancerization, providing insights into early events in the pathogenesis of NSCLC that may comprise targets for early treatment and chemoprevention. Cancer Res; 76(13); 3676-83. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27216194      PMCID: PMC5393446          DOI: 10.1158/0008-5472.CAN-15-3064

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  A risk model for prediction of lung cancer.

Authors:  Margaret R Spitz; Waun Ki Hong; Christopher I Amos; Xifeng Wu; Matthew B Schabath; Qiong Dong; Sanjay Shete; Carol J Etzel
Journal:  J Natl Cancer Inst       Date:  2007-05-02       Impact factor: 13.506

Review 2.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

Review 3.  Early stage lung cancer: progress in the last 40 years [corrected].

Authors:  Silvia Novello; Hisao Asamura; Jose Bazan; David Carbone; Peter Goldstraw; Dominique Grunenwald; Umberto Ricardi; Johan Vansteenkiste
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

Review 4.  Translating the transcriptome into tools for the early detection and prevention of lung cancer.

Authors:  Yaron B Gesthalter; Jessica Vick; Katrina Steiling; Avrum Spira
Journal:  Thorax       Date:  2015-01-27       Impact factor: 9.139

5.  Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma.

Authors:  Johan Staaf; Sofi Isaksson; Anna Karlsson; Mats Jönsson; Leif Johansson; Per Jönsson; Johan Botling; Patrick Micke; Bo Baldetorp; Maria Planck
Journal:  Int J Cancer       Date:  2012-10-20       Impact factor: 7.396

Review 6.  Lung cancer preneoplasia.

Authors:  Ignacio I Wistuba; Adi F Gazdar
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

7.  Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.

Authors:  Humam Kadara; Li Shen; Junya Fujimoto; Pierre Saintigny; Chi-Wan Chow; Wenhua Lang; Zuoming Chu; Melinda Garcia; Mohamed Kabbout; You-Hong Fan; Carmen Behrens; Diane A Liu; Li Mao; J Jack Lee; Kathryn A Gold; Jing Wang; Kevin R Coombes; Edward S Kim; Waun Ki Hong; Ignacio I Wistuba
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-19

8.  Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers.

Authors:  M A Nelson; J Wymer; N Clements
Journal:  Cancer Lett       Date:  1996-05-15       Impact factor: 8.679

9.  Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer.

Authors:  Frank McCaughan; Jessica C M Pole; Alan T Bankier; Bernard A Konfortov; Bernadette Carroll; Mary Falzon; Terence H Rabbitts; P Jeremy George; Paul H Dear; Pamela H Rabbitts
Journal:  Am J Respir Crit Care Med       Date:  2010-03-18       Impact factor: 21.405

10.  Haplotype-based profiling of subtle allelic imbalance with SNP arrays.

Authors:  Selina Vattathil; Paul Scheet
Journal:  Genome Res       Date:  2012-10-01       Impact factor: 9.043

View more
  25 in total

1.  Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin.

Authors:  Sarah A Comerford; Elizabeth A Hinnant; Yidong Chen; Hima Bansal; Shawn Klapproth; Dinesh Rakheja; Milton J Finegold; Dolores Lopez-Terrada; Kathryn A O'Donnell; Gail E Tomlinson; Robert E Hammer
Journal:  JCI Insight       Date:  2016-10-06

2.  Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.

Authors:  Humam Kadara; Smruthy Sivakumar; Yasminka Jakubek; F Anthony San Lucas; Wenhua Lang; Tina McDowell; Zachary Weber; Carmen Behrens; Gareth E Davies; Neda Kalhor; Cesar Moran; Randa El-Zein; Reza Mehran; Stephen G Swisher; Jing Wang; Jianjun Zhang; Junya Fujimoto; Jerry Fowler; John V Heymach; Steven Dubinett; Avrum E Spira; Erik A Ehli; Ignacio I Wistuba; Paul Scheet
Journal:  Am J Respir Crit Care Med       Date:  2019-09-15       Impact factor: 21.405

Review 3.  Epigenetic Biomarkers in Colorectal Cancer.

Authors:  Mukesh Verma; Vineet Kumar
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

4.  Directional allelic imbalance profiling and visualization from multi-sample data with RECUR.

Authors:  Yasminka A Jakubek; F Anthony San Lucas; Paul Scheet
Journal:  Bioinformatics       Date:  2019-07-01       Impact factor: 6.937

5.  Large-scale analysis of acquired chromosomal alterations in non-tumor samples from patients with cancer.

Authors:  Y A Jakubek; K Chang; S Sivakumar; Y Yu; M R Giordano; J Fowler; C D Huff; H Kadara; E Vilar; P Scheet
Journal:  Nat Biotechnol       Date:  2019-11-04       Impact factor: 54.908

Review 6.  Genome evolution in ductal carcinoma in situ: invasion of the clones.

Authors:  Anna K Casasent; Mary Edgerton; Nicholas E Navin
Journal:  J Pathol       Date:  2016-11-27       Impact factor: 7.996

Review 7.  Evolution and progression of Barrett's oesophagus to oesophageal cancer.

Authors:  Sarah Killcoyne; Rebecca C Fitzgerald
Journal:  Nat Rev Cancer       Date:  2021-09-20       Impact factor: 60.716

8.  RS1 gene is a novel prognostic biomarker for lung adenocarcinoma.

Authors:  Tao Zhang; Guowei Cheng; Ping Chen; Yue Peng; Lei Liu; Runze Li; Bin Qiu
Journal:  Thorac Cancer       Date:  2022-05-15       Impact factor: 3.223

9.  Evolutionary dynamics in pre-invasive neoplasia.

Authors:  Christopher Abbosh; Subramanian Venkatesan; Samuel M Janes; Rebecca C Fitzgerald; Charles Swanton
Journal:  Curr Opin Syst Biol       Date:  2017-04

10.  Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples.

Authors:  Alexander Semaan; Vincent Bernard; Jaewon J Lee; Justin W Wong; Jonathan Huang; Daniel B Swartzlander; Bret M Stephens; Maria E Monberg; Brian R Weston; Manoop S Bhutani; Kyle Chang; Paul A Scheet; Anirban Maitra; Yasminka A Jakubek; Paola A Guerrero
Journal:  Clin Cancer Res       Date:  2020-11-13       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.